MARK YOUR CALENDARS! hATTR Amyloidosis Advocacy Webinars
Hereditary Amyloidosis Canada invites you to a join us on May 13, May 20 and May 27, 2020 at 8:00 p.m. EDT for our first-ever interactive webinar series for Canadian hATTR patients, families and caregivers to learn about the fundamentals of advocacy and HAC’s recently...
Hereditary Amyloidosis Community Hopes Positive Funding Recommendations for New Treatments Lead to Swift Access for Patients
Ancaster, ON, March 2, 2020 -- TTR Amyloidosis Canada is joined by the Regroupement québécois des maladies orphelines (RQMO) in commending the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et...
CALL FOR PROPOSALS
TTR Amyloidosis Canada and Regroupement québécois des maladies orphelines (RQMO) are pleased to announce a Call for Proposals for Unfolding Transthyretin Amyloidosis: The Akcea Canada Young Investigator Grants Program. This new research program will...
Hereditary Amyloidosis Canada and Regroupement québécois des maladies orphelines Announce Akcea Canada Young Investigator Grant Program
-First Canadian Program to Stimulate Research into Transthyretin Amyloidosis - Toronto, ON and Montreal, QC , December 19, 2019 -- TTR Amyloidosis Canada and Regroupement québécois des maladies orphelines (RQMO) announced today that they have...
2nd European Meeting for ATTR Amyloidosis for Doctors and Patients – September 1-3, 2019
The 2nd European Meeting for ATTR Amyloidosis for Doctors and Patients took place in Berlin, Germany. In attendance were 300 participants, including over 200 doctors from 21 countries across the globe. Patients and caregivers came from Japan, South Korea, Venezuela,...
2019 Biennial ATTR (Familial) Meeting
From October 25-27, 2019, I was able to attend this meeting in Chicago, arranged by Amyloidosis Support Groups. The goal of the conference was to inform and share information about amyloidosis, current and future treatments, clinical trials and research updates....
November 16 webinar recording now available!
Thank you to all who were able to join us on November 16 for the Unfolding hATTR: Cardiac Amyloidosis presentation with Dr. Diego Delgado. In case you missed it, you can listen to a recording of the webinar here: If you have any future webinar topic...
NOVEMBER 16 WEBINAR – You’re Invited!
Unfolding hATTR: Update on Cardiac Amyloidosis Are you or a loved one living with hereditary ATTR (hATTR) amyloidosis? On behalf of Hereditary Amyloidosis Canada, we’d like to invite you to our first webinar for Canadian patients, caregivers and family members to help...
Onpattro™ (patisiran) is now approved in Canada
Alnylam Pharmaceuticals, Inc. Announce Health Canada’s Approval of Onpattro™ (patisiran) for the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. To learn more, please...
United Kingdom endorses the use of inotersen (Tegsedi) to treat patients with hATTR
On April 16, 2019 the National Institute for Health and Care Excellence (NICE) releases its final guidance recommending inotersen (Tegsedi) be placed on England’s National Health Service for the treatment of nerve damage from hereditary transthyretin-mediated...
Sign up to Stay in Touch!
Get important updates, including Canadian-focused news and information about ATTR, delivered to your inbox.
*By submitting this form, you are consenting to receive emails from Hereditary Amyloidosis Canada. You can revoke your consent to receive emails at any time by using the unsubscribe link, found at the bottom of every email.